Skip to main content
. Author manuscript; available in PMC: 2014 Jun 6.
Published in final edited form as: Pharmacogenet Genomics. 2013 Nov;23(11):591–596. doi: 10.1097/FPC.0b013e32836533a5

Table 1.

Patient demographics and relative genetic contribution (rGC) to nevirapine AUC0–6h

European
Americans
African
Americans
Sample Size n 11 6
Gender Male (%) 4 (36) 1 (17)
Female (%) 7 (64) 5 (83)
Age (years) Median 45 49
Range 29 – 57 33 – 74
Nevirapine AUC0–6h (mg/L*hr)1 SDw2 2.39 5.34
SDb2 24.9 54.7
Estimated Relative Genetic Component rGC2 (95% CI) 0.904 (0.64 – 0.97) 0.902 (0.42 – 0.98)
F 10.4 10.2
p 0.02 0.01
1

SDw2 is within individual variation and SDb2 is within subjects variation.

2

Estimated relative genetic component